GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » Operating Margin %

Sierra Oncology (Sierra Oncology) Operating Margin % : 0.00% (As of Mar. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Sierra Oncology's Operating Income for the three months ended in Mar. 2022 was $-27.88 Mil. Sierra Oncology's Revenue for the three months ended in Mar. 2022 was $0.00 Mil. Therefore, Sierra Oncology's Operating Margin % for the quarter that ended in Mar. 2022 was 0.00%.

The historical rank and industry rank for Sierra Oncology's Operating Margin % or its related term are showing as below:


SRRA's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -158.97
* Ranked among companies with meaningful Operating Margin % only.

Sierra Oncology's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Sierra Oncology's Operating Income for the three months ended in Mar. 2022 was $-27.88 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 was $-102.65 Mil.


Sierra Oncology Operating Margin % Historical Data

The historical data trend for Sierra Oncology's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology Operating Margin % Chart

Sierra Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only - - - -21,647.00 -

Sierra Oncology Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sierra Oncology's Operating Margin %

For the Biotechnology subindustry, Sierra Oncology's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sierra Oncology's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sierra Oncology's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Sierra Oncology's Operating Margin % falls into.



Sierra Oncology Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Sierra Oncology's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-94.585 / 0
= %

Sierra Oncology's Operating Margin % for the quarter that ended in Mar. 2022 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=-27.883 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sierra Oncology  (NAS:SRRA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Sierra Oncology Operating Margin % Related Terms

Thank you for viewing the detailed overview of Sierra Oncology's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sierra Oncology (Sierra Oncology) Business Description

Traded in Other Exchanges
N/A
Address
1820 Gateway Drive, Suite 110, San Mateo, USA, 94404
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Executives
Vivo Opportunity Fund Holdings, L.p. director, 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner officer: Chief Reg & Tech Ops Officer C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson officer: General Counsel C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson director, 10 percent owner C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal director, 10 percent owner C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair director C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459

Sierra Oncology (Sierra Oncology) Headlines

From GuruFocus

Sierra Oncology Announces Proposed Public Offering of Common Stock

By Business Wire Business Wire 01-25-2022

Abingworth LLP Goes on Buying Spree in 1st Quarter

By GuruFocus Research GuruFocus Editor 05-18-2022

New Leaf Venture Partners, L.L.C.'s Top 5 Sells of the 4th Quarter

By GuruFocus Research GuruFocus Editor 02-07-2023